BridgeBio reported positive top-line results from Propel 3, a global Phase 3 trial of oral infigratinib in children with achondroplasia, meeting the primary endpoint for annualized height velocity (AHV). The trial showed statistically significant gains in AHV versus placebo, with treatment differences ranging from roughly +1.74 cm/year to +2.10 cm/year depending on analysis. Company statements indicate plans to meet regulators and prepare filings later this year. BridgeBio said the drug was well tolerated; reported adverse events included transient hyperphosphatemia that did not require dose changes. The result adds to a recent string of late‑stage wins for BridgeBio and positions oral infigratinib as a potential competitor to injectable therapies. Analysts and clinicians will watch how regulators size up the benefit versus established options from BioMarin and Ascendis. If approved, an oral FGFR‑targeting therapy could change the competitive dynamics for achondroplasia treatment and broaden patient choices.